Despite So-So Sales To Date, HGS Sees Promising Launch For Benlysta
This article was originally published in The Pink Sheet Daily
Executive Summary
Third quarter U.S. sales of $18.8 million disappoint some analysts, but HGS emphasizes growing patient base and multi-part commercialization plan still being implemented.
You may also be interested in...
HGS Calls For Confidence In Slow, Steady Ramp-Up For Benlysta
In the fourth quarter, the new SLE drug continued its slow sales growth – HGS said rheumatologists are still largely in trial mode, testing the drug in a few patients and gaining confidence in its benefits.
GSK Gears Up To Fight NICE On Benlysta Setback
In preliminary assessment, NICE says it won't recommend GSK's Benlysta for systemic lupus erythematosus as it is too expensive, but a population subgroup analysis may be able to change the ruling.
HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions
The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.